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Abstract
Background: Among adult kidney transplant recipients, non-adherence to immunosuppressive medications is the
leading predictor of poor outcomes, including rejection, kidney loss, and death. An alarming one-third of kidney
transplant patients experience medication non-adherence even though the problem is preventable. Existing
adherence interventions have proven marginally effective for those with acute and chronic illnesses and ineffective
for adult kidney transplant recipients. Our purpose is to describe the design and methods of the MAGIC
(Medication Adherence Given Individual SystemCHANGE™) trial
Methods/Design: We report the design of a randomized controlled trial with an attention-control group to test an
innovative 6-month SystemCHANGE™ intervention designed to enhance immunosuppressive medication adherence
in adult non-adherent kidney transplant recipients from two transplant centers. Grounded in the Socio-Ecological
Model, SystemCHANGE™ seeks to systematically improve medication adherence behaviors by identifying and
shaping routines, involving supportive others in routines, and using medication taking feedback through small
patient-led experiments to change and maintain behavior. After a 3-month screening phase of 190 eligible adult
kidney transplant recipients, those who are <85 % adherent as measured by electronic monitoring, will be
randomized into a 6-month SystemCHANGE™ intervention or attention-control phase, followed by a 6-month
maintenance phase without intervention or attention. Differences in adherence between the two groups will be
assessed at baseline, 6 months (intervention phase) and 12 months (maintenance phase). Adherence mediators
(social support, systems-thinking) and moderators (ethnicity, perceived health) are examined. Patient outcomes
(creatinine/blood urea nitrogen, infection, acute/chronic rejection, graft loss, death) and cost effectiveness are to be
examined.
Discussion: Based on the large effect size of 1.4 found in our pilot study, intervention shows great promise for
increasing adherence. Grounded in the socio-ecological model, SystemCHANGE™ seeks to systematically improve
medication adherence behaviors by identifying and shaping routines, involving supportive others in routines, and
using medication taking feedback through small patient-lead experiments to change and maintain behavior.
Medication adherence will be measured by electronic monitoring. Medication adherence persistence will be
examined by evaluating differences between the two groups at the end of the 6-and 12- month phases. Mediators
and moderators of medication adherence will be examined. Patient outcomes will be compared and a
cost-effectiveness analysis will be conducted.
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Background
For adults who have a kidney transplant, the leading pre-
dictor of rejection, kidney loss, death and their attendant
costs is immunosuppressive medications non-adherence
[1–5] with an alarming one-third of kidney transplant
recipients experiencing this preventable problem [6–8].
According to meta-analysis, predictors of medication
nonadherence are nonwhite ethnicity, poorer social sup-
port and poorer perceived health [8]. Patients’ most fre-
quent barrier to adhering to immunosuppressive
medication is forgetting [9]. Even minor deviations from
adherence have shown negative effects, though the pre-
cise extent of poor outcomes stemming from nonadher-
ence is not yet clear [10–13]. Traditionally, intervention
studies have aimed at boosting adherence target cogni-
tion (knowledge, attitudes, beliefs) and behavioral skills.
However, these have proven only marginally effective for
individuals with acute and chronic illnesses [14–18] and
ineffective for adult kidney transplant recipients [19–21].
In a sample of kidney transplant recipients, we test the
innovative and successful SystemCHANGE intervention,
which is grounded in the Socio-Ecological Model [22–25].
This approach is a paradigm shift in behavioral interven-
tions because it focuses on redesigning the system of the
interpersonal environment and daily routines linked to
health behavior, rather than focusing on increasing indi-
viduals’ motivation and intentions to improve their adher-
ence [22, 26, 27]. Using a four-pronged, patient-centered
approach, we: (1) assess individual systems (including im-
portant others who shape medication taking), how they
influence medication taking and the individual’s proposals
for improving medication adherence, (2) implement the
proposed individual systems solutions for improving ad-
herence, (3) track adherence data, and (4) evaluate adher-
ence data through small experiments. The effect size of
1.4 found in the SystemCHANGE pilot work was a nearly
four-fold greater effect size of most other previous adher-
ence interventions [28].
The effectiveness of interventions to improve medica-
tion adherence (MA) in the acute and chronically ill gen-
eral population has been examined by numerous
systematic reviews and meta-analyses [14–16, 29–35].
Typically psychological theories guide interventions to en-
hance knowledge through education, attitude through
counseling, and behavior through skills training. Even with
multi-faceted interventions, effect sizes in meta-analyses
have been very small. Narrative reviews corroborate find-
ings from meta-analysis that limited benefits occur with
interventions focused on motivation and intention. Only
about 50 % of studies found statistically significant im-
provements in MA. Equally disappointing results have
been noted in transplant intervention studies which have
also focused only on motivation and intention [19–21,
36–40]. Limitations of these studies included: 1) atheoreti-
cal approaches, 2) testing interventions that targeted
motivation and intentions, 3) a lack of attention to envir-
onmental influences on routines and habits, 4) a lack of
timely feedback on medication-taking, and 5) no evalu-
ation of intervention cost-effectiveness. This study proto-
col addresses these limitations.
Methods
Aims
The primary aim of the trial is to determine whether the
SystemCHANGE™ intervention is more effective than
the attention control intervention in improving MA in
adult kidney transplant recipients at the completion of
the intervention and maintenance phases. We
hypothesize adult kidney transplant recipients participat-
ing in the SystemCHANGE™ intervention will have
higher immunosuppressive MA rates than those partici-
pating in the attention control at the completion of
intervention and maintenance phases. A secondary aim
is to examine the patterns of MA in this group. We will
determine when the intervention becomes effective (e.g.,
what “dose” is needed) and what the pattern of decay in
medication adherence is over time in both groups. Our
exploratory aims are to determine whether the System-
CHANGE™ intervention is more effective than the atten-
tion control in decreasing poor health outcomes (e.g.,
infection, acute/chronic rejection, graft loss, death, and
increasing creatinine/blood urea nitrogen,), to explore
potential mediators (social support and systems-
thinking) and moderators (ethnicity, perceive health and
level of medication nonadherence) of MA, and to deter-
mine whether the SystemCHANGE™ intervention is
cost-effective. We hypothesize patients in the System-
CHANGE™ intervention will demonstrate lower levels of
poor outcomes than attention controls at 12 months.
We also hypothesize the cost-effectiveness ratio for the
SystemCHANGE™ intervention will be less than the
cost-effective ratio for the attention-control intervention.
Design
This is a 4-year, two-center, randomized controlled trial,
that is single-blind (participants [Pps]) and uses a
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stratified sample block design with repeated measures.
We are comparing the SystemCHANGE™ intervention
to the attention control intervention in adult kidney
transplant recipients with existing medication nonadher-
ence documented by electronic monitoring. The
repeated-measures design provides longitudinal data
regarding medication nonadherence which allows us to
determine when the intervention becomes effective (to
determine if a lower dose of SystemCHANGE™, e.g.
shorter time of delivery, is possible). It also allows us to
track possible decay in medication nonadherence over
time following the intervention.
We are examining the experimental effect on the out-
come variable MA. During the 3-month screening phase,
all Pps are using electronic monitoring to document medi-
cation taking. Those who are adherent (MA rate of .85 %
or greater) exit the study. To prevent the “ceiling” effect,
those with documented medication nonadherence (MA
rate of less than .85 %) are stratified by low (<70 %), and
moderate (70-84 %) nonadherence, based upon our previ-
ous medication nonadherence pattern research [41]. They
then enter the intervention phase of the study and are
randomized into either the treatment (SystemCHANGE™
intervention) or the attention control group (attention
control condition). During the 6-month intervention
phase, all Pps receive a home visit at baseline plus six tele-
phone calls (at intervention months 1, 2, 3, 4, 5, 6). In
addition, Pps randomized into the SystemCHANGE™
intervention are also guided in implementing System-
CHANGE™ activities related to medication taking by the
Research Assistant (RA). Control group Pps receive RA-
provided education guided by healthy living patient educa-
tional materials. The maintenance phase begins after the
intervention and runs for an additional 6 months. This
phase examines how Pps maintain MA in the absence of
an intervention; however, we are continuing to use elec-
tronic monitoring to measure the outcome variable.
Health outcome and healthcare cost data are collected
during the intervention and maintenance phases.
Ethics, consent and permissions
Institutional Review Board (IRB) approval has been
obtained at the University of Missouri and the
University of Tennessee. The IRB approval at the
University of Missouri, which is the primary approv-
ing institution, is #1210944. Informed consent is
obtained from every participant prior to their involve-
ment in the study. We are collecting demographic
data from those who do not consent to the full study,
but who agree to provide this information. This al-
lows us to determine if any demographic differences
exist between those who decline to participate in the
study and those who consent.
Conceptual model
‘To Err Is Human’, the Institute of Medicine’s landmark
report on improving hospital safety, suggests moving
away from blaming the individual and instead making
the desired behavior more likely to occur by removing
barriers [37]. SystemCHANGE™ is consistent with mov-
ing away from the culture of “blame” and instead guid-
ing Pps to change their individual personal environment
[38]. Additionally, sustained motivation and continual
intention are necessary, but not sufficient for behavior
change [24, 25, 39].
Theoretical underpinning for SystemCHANGE™ have
been detailed elsewhere [38] but a brief overview is pro-
vided here. Grounded in the socioecological model of
Brofenbrenner, [40, 41] SystemCHANGE™ focuses on the
micro level systems of face-to-face influences on MA in the
person’s family, work, and social circles, and also on the
meso level which consists of the individual’s interrelated
micro level systems. Within this framework, System-
CHANGE™ supports patient-designed, interventionist-
guided, small experiments using Deming’s Plan-Do-Check-
Act cycle [42].
SystemCHANGE™ interventions have increased and
maintained physical exercise, [23, 24] reduced sleep dis-
orders, [22] reduced stress, [43] lowered asthma attacks,
[44] improved eating behaviors, [45] and enhanced care
of those with hypertension [46]. At the micro and meso
level, our recent systematic review of personal system
level interventions documents potential for improving
difficult-to-change behaviors such as MA [47]. The focus
of this study involves implementing the System-
CHANGE™ intervention with the patient at the micro
and meso personal level, not at the exo or large system
or community level.
Study sample and setting
Participants are being recruited from two kidney
transplant centers. The transplant centers’ staff
(transplant nurses and social workers) are using a
computer-generated list of random numbers pro-
vided by the study biostatistician to randomly select
190 potential Pps from a list of transplant patients
cared for at their respective transplant center (95
from University of Missouri [MU] and 95 from Uni-
versity of Tennessee [UT]). Staff telephone identified
patients and ask if they are willing to have a RA
contact them to discuss possible participation in a
study. If they are willing to be called, the RA will
contact them by telephone to review the study. If
the patient agrees to participate the electronic medi-
cation monitoring cap and diary will be mailed to
them, the cognitive screening exam administered,
and demographic information gathered.
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Eligibility and exclusions
Adult kidney transplant recipients meeting the following
criteria will be included: 1) age 18 years or older, 2) pre-
scribed at least 1 immunosuppressive medication taken
twice a day, 3) functioning kidney transplant (not on dia-
lysis), 4) has received a kidney-only transplant, 5) agree-
ment from the transplant physician and nephrologist
that the individual is able to participate in the study, 6)
able to speak, hear, and understand English as deter-
mined by the ability to participate and comprehend con-
versation about potential inclusion in the study, 7) able
to open an electronic medication monitoring cap as
assessed by the RA asking if there is any problem with
opening pill bottle caps, 8) able to administer immuno-
suppressive medications to self, 9) has a telephone or
has access to a telephone, 10) has no cognitive impair-
ment as determined by a score of 4 or greater on the 6-
item Telephone Mental Status Screen Derived from the
Mini-Mental Status Exam, 11) has no other diagnoses
that may shorten life span, such as metastatic cancer, 12)
is not currently hospitalized, 13) receives post-transplant
care by the Missouri or Tennessee transplant programs.
Patients who have had their transplants for various
lengths of time are being recruited because the variable
‘time since transplant’ has been shown to be an unreli-
able predictor of medication nonadherence [42–44]. Pa-
tients receiving other types of transplants are being
excluded from the study because MA varies between
transplant types [8]. Patients who receive a kidney re-
transplant are included since medication nonadherence
also occurs in this subset of kidney transplant recipients
[43, 45]. The few kidney transplant recipients who par-
ticipated in the pilot intervention study are excluded
from this study.
Randomization after allocation procedure
We will employ stratified randomization, which is di-
rected by a biostatistician. Participants with a MA
score <.85 will be randomly assigned to either the
treatment or control group by a computer-generated
block randomization scheme. We will also stratify by
moderate (84-70 %) and low (<70 %) adherence to
maintain balance between the treatment and
attention-control groups. Participant number is se-
quentially assigned in the order in which individuals
are consented. If a Pp drops out in the intervention
phase, the next enrolled Pp is assigned to the same
group (treatment or attention-control) as the drop out
was assigned. Although requiring RAs from both study
groups to be available at study enrollments appears ineffi-
cient, in our experience it is a great advantage to engage
new enrollees immediately in our treatment protocol and
thereby eliminate potential attrition between randomization
and the first intervention or control session.
Blinding
All study personnel except the biostatistician are
remaining blind to the group assigned until after eligibil-
ity is determined. Afterward, the PIs discloses the
assigned Pp code and provide their information to the
appropriate RA for the assigned intervention to begin.
Development of the SystemCHANGE™ intervention
Our previous qualitative studies of medication self-
management in adults and older adults indicate envir-
onmental structure and routines are important for
success [46, 47]. Strategies include maintaining rou-
tines (habits and linking medication taking with other
behaviors), reminder methods (cues, alarms, pillboxes,
and medication location), obtaining medications
(pharmacy routines) and involving a person who sup-
ports the medication taking environment. Conse-
quently, these strategies are incorporated into the
SystemCHANGE™ intervention to enhance medication
self-management which has traditionally been absent
from transplant patient education [48].
SystemCHANGE™ is delivered in various formats
(group versus individual) over different time frames (one
time to 12 weeks), and in several locations (home versus
community center) [49]. We are delivering the System-
CHANGE™ intervention in the kidney transplant recipi-
ents’ homes and over the telephone since many travel
long distances to a transplant center. This delivery ap-
proach facilitates the sustainability of the intervention.
The baseline SystemCHANGE™ home visit is approxi-
mately 1 hour and 20 minutes in length. Table 1 provides
an overview of the first step of the SystemCHANGE™ inter-
vention delivered during the home visit. During the second
step, which is delivered over the telephone 2 weeks after
the home visit, the RA and Pp recount the Pp’s discussion
with the important person(s) and the selected environmen-
tal solution identified during the home visit. The RA asks
the Pp to identify a date to implement the solution and en-
courages the Pp to continue using the electronic medica-
tion monitor. They schedule a time to speak by telephone
in 1 month to review the electronic medication monitor re-
port and evaluate progress.
During the next phase of the study, step 3, medication
taking goals and the “small experiments” are evaluated.
This occurs each month during a telephone call by the
RA to the Pp. The RA mails the electronic medication
monitor report to the Pp prior to the call during which
the RA asks the Pp “Tell me what you are learning about
medication taking. How to you think changes you have
made to routines are changing your medication taking?
Tell us about any other changes to medication taking
routines that you feel need to be made.” If adherence is
the same or worse as before, the RA encourages the Pp
to try another solution from the Possible Solutions list
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completed during the home visit. If medication taking is
improving, the RA encourages the Pp to continue that
approach. The RA reminds the Pp to share progress
through a storyboard by displaying the electronic medi-
cation monitoring reports in a prominent location, such
as the refrigerator.
After month 6 of the intervention phase, the RA closes
the intervention by discussing the Pp’s improvements.
The RA encourages the Pp to continue using the elec-
tronic medication monitor and diary for the next 6
months during the maintenance phase.
Attention-Control intervention
The 6-month attention-control intervention involves a
home visit and monthly phone calls at the same intervals as
the intervention group (at attention-control months 1, 2, 3,
4, 5, and 6). Rather than the SystemCHANGE™ interven-
tion, the attention-control Pps receive educational materials
developed by the International Transplant Nurses Society
that address healthy living after transplant [50]. The RA
calls Pps at 1, 2, 3, 4, 5 and 6 months to review the bro-
chure information and answer any questions about it. Time,
interval, frequency, and setting are all exactly the same for
the intervention and control groups. If attention-control
Pps raise questions about medications or medication-
taking, the RA directs them to discuss them with their
transplant team contact person.
At the end of month 6 of the intervention phase, the
RA closes the control by discussing the healthy post-
transplant information the Pp reviewed during the previ-
ous 6 months. The RA encourages Pps to continue using
the electronic medication monitor and diary for the next
6 months during maintenance phase.
Treatment fidelity
A detailed procedure manual provides specific informa-
tion about every facet of the interventions. To ensure
RA fidelity to the intervention and control arms, a
Fidelity Protocol Checklist is used during all Pp encoun-
ters where key elements of the protocol are documented
including number of intervention sessions, session dur-
ation, length of time between sessions, and intervention
steps (e.g. greeting the Pp, MEMS review, use of inter-
vention forms). Each element is rated as completed,
partially completed, not completed, or N/A. Field notes
are documented for every encounter, which could in-
clude Pp’s body language, environmental issues (e.g.
temperature, noise), and presence of others in the home.
Field notes for telephone contacts include background
noise, telephone line distortion, and any difficulty hear-
ing by RA or Pp.
Training the research assistants who deliver the
intervention
An expert in SystemCHANGE™ delivers content train-
ing to RAs who are baccalaureate-prepared RNs at the
study recruitment sites. To preserve intervention in-
tegrity, simulation and role play are used until the
RAs are applying the protocol consistently, as judged
by the expert using the SystemCHANGE™ protocol
checklist. In addition to teaching RAs System-
CHANGE™ principles and steps, the expert guides
RAs as they practice using the study protocol and
protocol checklist on a sample of Pps. To ensure the
highest level of RA protocol knowledge and skills,
training sessions also include role playing of disruptive
situations for both interventions, and delivering both
intervention for a different behavior change such as
exercise or diet. SystemCHANGE™ RAs are trained
separately from the control RAs. The expert provides
RAs feedback on performance, and RAs retrain as ne-
cessary until they have achieved 100 % intervention
protocol integrity.




Overview-challenges of medication taking (takes time, not your fault, should not have to try harder, medications
should be in the right place at the right time, habits and routines are key to success), focus on routines and
conducting small experiments to improve medication taking, review 4 steps of SystemCHANGETM, and discuss how
RA will guide Pp through the process of improvement.
Review of electronic medication
self-monitoring report
RA guides Pp’s review of MEMS report details; Pp’s personal MEMS report reviewed from screening phase.
Goal setting RA discusses Pp’s medication taking goals; encouraged to have goal of 100 % medication adherence.
Determining Process Owners RA assists Pp in identifying important people in medication taking process using Important People worksheet.
Lifestyle Routines RA assist Pp in identifying lifestyle routines using the Life Routines worksheet.
Cycles RA assists Pp in identifying cyclical nature of daily, weekly and monthly routines using the Cycles worksheet.
Possible Solutions for Change RA and Pp collaboratively consider possible environmental changes to enhance medication taking routines.
Participant scores ideas on Possible Solutions Scale.
Storyboard RA encourages Pp to post MEMS report as a storyboard for success.
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Primary outcome - medication adherence
Table 2 provides an overview of study measures and out-
comes. The MA calculation method has been previously
described but will be briefly described here [41]. A 0.5 is
assigned if the dose of the immunosuppressive medica-
tion is taken within a 3-hour window (+/-1.5 hours of
the prescribed time); 0.25 is assigned if the dose of the
immunosuppressive medication is not within the 3-hour
window but is taken within a 12-hour window (+/-6
hours of the prescribed time), and 0 is assigned if the
dose of the immunosuppressive medication is not taken
within a 12-hour window (+/-6 hours of the prescribed
time, i.e., if the dose was missed). On each day, an indi-
vidual is assigned a score of 0, 0.25, 0.50, 0.75 or 1
points (p. 526).
The primary outcome is medication adherence mea-
sured by the MEMSCap™ Medication Event Monitoring
System SmartCap® (WestRock, USA & Switzerland). The
system is comprised of two parts: a standard plastic vial
with a threaded opening and the SmartCap® which has
an LCD readout that displays the number of doses taken
in the past 24 hours and the hours elapsed since last
dosing. A micro-electronic circuit in the SmartCap® reg-
isters the date and time when the top is opened and
closed to create a medication “event”. Time-stamped
medication events stored in the MEMS® 6 can be trans-
ferred at any time through the MEMSCap™ Wireless
Reader to medAmigo. The medAmigo portal is a web-
based application used to securely download and
centrally store medication dosing history (www.medA
migo.com). MedAmigo performs the MA score calcula-
tions. Although no gold standard measure exists for
MA, most researchers consider electronic monitoring
caps the best method. It is the only adherence measure
that can accurately assess this variable, as recall memory
is unlikely to be accurate enough for self-reports to pro-
vide valid data regarding the exact timing of doses over
a period of time. The batteries for the MEMS 6 have a
36 month life and can store up to 3800 medication
events. This battery life has been shown to be more than
sufficient for capturing 12 months of medication taking
activity [51]. The MEMS has been shown to be reliable
in temperatures from -20 °C to 70 °C and in up to 95 %
humidity [52], are accurate to within 2 minutes per
month, and have a reported 2 % failure rate [52, 53].
The ability of electronic monitoring to provide a precise
assessment of dosage timing is particularly advantageous
as studies are beginning to emerge that reveal the im-
portance of the interval between doses in explaining the
relationship between adherence and clinical outcomes in
other chronic illnesses [54, 55].
Both intervention and attention-control groups use
MEMS for 6 months after the 3-month screening phase.
This length of time allows adequate time to capture
changes in medication-taking behavior [56]. One twice-
daily prescribed medication are monitored because pre-
vious research has indicated that monitoring a second
medication does not provide additional MA information
[53]. The monitored immunosuppressive medication is
randomly selected by the RA. Random selection of the
monitored immunosuppressive medication occurs as fol-
lows: The RA numbers all of the twice-daily administered
immunosuppressive medications on the Demographics
Form. Most Pps will take two immunosuppressive medi-
cations twice daily. In this case, the RA will flip a coin to
determine which medication will be placed in the MEMS
bottle. In the event that the patient has greater than two
immunosuppressive medications taken twice daily, the RA
will enter the number into a random numbers generator
and have the Pp monitor the randomly selected immuno-
suppressive medication.
Pps are trained on use of the MEMS cap by the RAs.
They are instructed to only remove the randomly se-
lected immunosuppressive medication from the MEMS
cap and bottle. If a pillbox is used for medications,












Creatinine √ √ √
Blood urea nitrogen √ √ √
Acute rejection √ √ √
Chronic rejection √ √ √
Infection √ √ √
Death √ √ √
Potential Mediators
Social Support √ √
Perceived Health √ √










observation, and ER visits
√ √ √
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colored disks/“Tic-Tacs” are placed in the pillbox to
remind the Pp to ingest the medication from the
MEMS bottle. During the screening phase, at weeks 1
and 8, the RAs telephones the Pp to ask if they are
using the MEMS and MEMS diary and if they have
any questions about using them. Those Pps who do
use a pillbox are asked if they are using the “Tic-Tacs” to
remind them to ingest from the MEMS bottle. If there are
any deviations from the procedure, the RAs will re-train
the Pps.
Beginning the day after the intervention Pps are
instructed how to use the cap. Cap openings will be re-
corded and a cumulative medication taking record gen-
erated. This record is sent to the SystemCHANGE™
intervention Pps and reviewed with them at baseline and
months 1, 2, 3, 4, 5, and 6. These reports contain a sum-
mary report with graphic representation of individual
bottle openings and closings within the established time
window of +/-1.5 hours, the hours elapsed since the
previous opening, missed doses, and drug holidays. The
attention-control intervention group will continue to use
the MEMS but will not be sent a report since this is the
“Study” step of the SystemCHANGE™ intervention.
Participants mail the MEMS diary to the RA to docu-
ment any accidental cap openings, openings when no
medication was ingested, (e.g. when refilling MEMS bot-
tle), and early openings when a medication was removed
early to be administered later (pocketing a dose), but on
time, (e.g. clinic appointments). As in our preliminary
work, we will correct MEMS cap data using the MEMS
diary. The diary successfully corrects any invalid data
from MEMS opening when medications were not
ingested or were ingested at a time different from the
time the MEMS was opened [57]. After these correc-
tions, we assume that each cap removal represents the
patient ingesting one dose of the prescribed immuno-
suppressant. To enhance accuracy, Pps are trained on
use of the MEMS diary. Pps are given specific examples
of when the diary should and should not be used. They
are trained to store the diary with the MEMS bottle.
Training continues until the Pp achieves 100 % accuracy
using the MEMS diary with 4 MEMS diary test scenarios
(i.e., accidental opening, early opening [pocketing dose],
opened but no medication administered, and diary stor-
age). This approach to using a MEMS diary to correct
adherence data has been validated in several previous re-
search studies [19–43, 53, 57].
Additional outcomes
The following clinical outcomes will be collected retro-
spectively for all three phases: Blood creatinine, BUN
level, acute and chronic rejection, infection, health-
related quality of life and death from the medical record
and from primary data collection. Acute and chronic
rejection episodes will include those that are biopsy-
proven and/or medically treated (3-day dose of intraven-
ous prednisone) as such. Infection episodes will include
those in which the blood, sputum, and/or urine culture
is positive for an abnormal organism. Deaths will be re-
ported from the transplant team.
Cost-effectiveness
The primary endpoint of cost-effectiveness measures will
be the incremental cost-effectiveness ratio (ICER) of the
SystemCHANGE™ intervention relative to the attention-
control, which assesses the incremental cost per health-
related quality-adjusted life year gained. The perspective
of cost-effectiveness is a third-party payer. A micro-
costing approach will be used to measure the interven-
tion’s resource use, based on a log of resource use for
each intervention. The resources used for the delivery
intervention in the interventional and the control group
will be tracked over the study period. The Pps will track
the type and quantity of medical services consumed
(doctor’s office, clinic, hospital, medication). The unit
cost of personnel time will be based on actual hourly sal-
ary rates and fringe benefits. Unit costs of each
hospitalization, ER visit, clinic visit, and physician fee
will be estimated based on Medicare’s average reim-
bursement rate. The unit cost of medication will be esti-
mated from the average wholesale price plus the
dispensation fee of 2 %. To determine the number of
quality-adjusted life years over the observational period,
the weight will be multiplied by the number of days in
the observational period. All cost measures will be ad-
justed to the constant U.S. dollar. Sensitivity analyses
will examine key parameters that may affect ICERs.
Potential moderators and mediators
Perceived health status, a potential moderator, will be
measured by one question, “In general, how would you
say your health is?” Respondents select excellent, very
good, good, fair, or poor. Perceived health status reflects
people’s overall perception of their health, including
both physical and psychological dimensions [58]. The
question has good reliability and validity [58]. Ethnicity
will also be examined as a moderator.
Potential mediators are examined including social sup-
port and systems-thinking. We measure social support
using the Social Support Appraisals Index, a 23-item
self-administered, self-report scale measuring the degree
to which a person feels cared for, respected, and involved
with family and friends [59]. Respondents strongly agree,
agree, disagree, or strongly disagree with each statement.
Total scores range from 23 to 92. After reversing the
negatively stated items, low scores indicate high levels of
support. Typically, subscale scores for family and friends
are calculated. The instrument has been used with adult
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kidney transplant recipients [43, 60]. Data from 10 sam-
ples indicate that the scale had good internal reliability,
with Cronbach’s alphas ranging from .80 to .90 [59]. The
scale also showed stability over a six-week interval, with
reliability scores of .80. Convergent validity has been
demonstrated with significant associations to seven
other appraisal measures. Moreover, adequate concur-
rent, and divergent validity with other perceived support
measures was demonstrated.
Personal Systems Thinking will be measured by Systems
Thinking Survey (adapted for patients), a 20-item scale
using a 5-point Likert response scale developed by Drs.
Dolansky and Moore. The scale measures perceptions of
personal system behaviors [61]. It has good reliability and
construct and discriminate validity [62]. Test-retest was
0.74 and Cronbach’s Alpha was 0.89 [62]. The tool discrimi-
nated between those receiving high and low or no System-
CHANGE training (p=.05 and .01, respectively).
Statistical analysis
Sample size and power calculations are based on com-
paring expected change in medication adherence rate of
patients in each group at six months - an expected ad-
herence mean difference of 10 % based on our pilot
study findings and the literature. We use an alpha of .05
and provide for 90 % power to detect indicated effect
sizes in this two-arm randomized study. An effect size
difference of 70 % is based on a conservative estimate of
our pilot work. A sample size of 46 older KT recipients
per group (final total sample 92) will meet these as-
sumptions and provide sufficient power. Recruitment
and retention rates are calculated from our pilot study,
other adherence studies at the same sites, and are docu-
mented in one similar RCT adherence study in older KT
recipients [63, 64]. We selected an adherence rate of
85 % to divide the adherers from the non-adherers based
upon our preliminary work describing 4 clusters of KT
medication adherers: those who (1) take medications on
time (1.0-.85 MA rate), (2) take medications on time with
late/missed doses (.84-.70 MA rate), (3) rarely take medi-
cations on time and who were late with morning and/or
evening doses (.69-.20 MA rate), and (4) missed many
doses (<.20). Even minor deviations in dosing adherence
lead to poor outcomes, though no studies have deter-
mined the criterion adherence “dose” that distinguishes
good and poor outcomes.
Appropriate descriptive analyses will be performed to
examine distributional characteristics for collected mea-
sures, as well as to summarize changes over time as a
function of group assignment. During this initial phase,
we will explore bivariate relationships among primary
and secondary outcome measures and variables thought
to affect medication adherence. In addition, we will con-
duct analyses to determine whether the randomly
assigned groups are equivalent at the start of the study
on the demographic and other measures collected at
baseline. Before hypothesis-testing analyses are con-
ducted, exploratory analyses will be performed to exam-
ine the effect of various mediators and moderators on
the relationship between intervention, adherence, and
clinical outcome. The results of these analyses will deter-
mine what additional variables will be incorporated in
the subsequent hypothesis testing (e.g., analysis of
covariance).
Our primary analysis assesses whether the System-
CHANGE™ intervention is more effective than the
attention-control intervention in increasing MA in adult
kidney transplant recipients at the completion of the 6-
month intervention and 6-month maintenance phases.
We hypothesize that adult kidney transplant recipients
receiving the SystemCHANGE™ intervention will have
higher immunosuppressive MA rates than the attention-
control group at the completion of intervention and
maintenance phases. Since rate responses will most
likely violate the normality assumption, the non-
parametric method, Mann- Whitney test, will be used
for comparing the two groups. However if the normal
assumption is satisfied through transformation or as raw
data measures, t-test will be applied for group compari-
son. Possible covariates resulting from demographic data
and screening phase MA will be included in the analysis
to adjust for possible bias.
Our secondary analysis assesses the MA patterns in
both the SystemCHANGE™ and attention-control
groups. Specifically we are interested in determining
when the intervention becomes effective (e.g., what
“dose” is needed) and the pattern of decay in MA over
time in both groups. The dependent variable for these
research questions are the repeated measurements of
immunosuppressive MA rates at 12 time points [i.e. 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 months] and the inde-
pendent variable is group assignment and time effect.
Poisson regression analysis will be used for these ques-
tions. Proc Nlmixed procedure in SAS will be used for
Poisson regression modeling. In order to answer the hy-
pothesis we will test for group-by-time interaction to
test if the two groups have different time profiles for
MA or not. Possible covariates resulting from demo-
graphic data and screening phase MA will be included
in the model to adjust for possible bias. Repeated mea-
sures from the same Pp will be accounted for using a
random effect in the model.
Our exploratory analyses focuses on three aims: 1) to
determine whether the SystemCHANGE™ intervention is
more effective than the attention-control intervention in
decreasing poor health outcomes (e.g. increasing creatin-
ine/BUN, infection, acute/chronic rejection, graft loss,
death), 2) to evaluate the role of potential mediators
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(social support, and systems-thinking) and moderators
(ethnicity perceived health and level of medication non-
adherence) of MA and health outcomes in adult kidney
transplant recipients receiving the SystemCHANGE™
intervention, and 3) to determine if the System-
CHANGE™ intervention is cost-effective.
We expect to observe lower levels of poor health out-
comes in the SystemCHANGE™ group as compared to
the control group. The dependent variables are the di-
chotomous outcomes such as, infection, acute and
chronic rejection, graft loss, and death and numeric out-
comes such as creatinine, and BUN.
The independent variable is group assignment. Chi-
square tests will be applied to estimate and test the rela-
tionships between dichotomous outcome variables and
the independent variable. For continuous outcomes vari-
ables t test or Mann-Whitney test will be conducted to
test for group effect depending on the satisfaction of
normality assumption.
Our secondary exploratory aim is to evaluate the role
of potential mediators and moderators of MA and health
outcomes in adult kidney transplant recipients receiving
the SystemCHANGE™ intervention and recipients
receiving the attention-control intervention. We
hypothesize that exploring potential mediators and mod-
erators in the analyses will enhance the interpretation of
treatment effect on MA. To test for mediator effect, the
dependent variable is MA and the independent variable
is treatment group. Potential mediators are social sup-
port and systems thinking. Poisson regression will be ap-
plied to estimate the mediator effect [65] and the Sobel
test [66] will be used to test if the mediator effect is sig-
nificant. Changes in the variance with mediator in the
models will be estimated and reported as part of the
analysis results. To test for moderator effect, the
dependent variable is MA and the independent variable
is treatment group. Potential mediators are ethnicity
group, perceived health and MA level (different strata).
Poisson regression will be applied to estimate and test
for possible moderator effect through interaction terms
between the independent variable and moderator [65].
Our third exploratory aim is to determine if the System-
CHANGE™ intervention is cost-effective. Our hypothesis is
the cost for the SystemCHANGE™ intervention will be less
than the cost for the attention-control intervention. To de-
termine the cost-effectiveness of the SystemCHANGE™
intervention compared to the attention-control interven-
tion, both intervention and resource use costs will be evalu-
ated and compared to MA change. A cost-effectiveness
analysis will be performed at the end of the intervention
period and again at the end of the maintenance period. If
there is no treatment effect, a cost-analysis will not be
performed. The analysis performed at the end of the
maintenance period will be cumulative, incorporating
costs and benefits incurred throughout the project. A
cost-effectiveness analysis, performed at the end of the
maintenance period (calculated for both the intervention
and maintenance periods), will evaluate both intervention
and control, and resource use costs which will be com-
pared to adherence change. The sum of the total inter-
vention and control costs and resource use costs will be
the numerators for testing this hypothesis. The change in
adherence (from baseline to end of intervention [or end
of maintenance] period) will be the denominator. We will
identify all direct intervention costs related to the inter-
vention and the control (planning, designing, and imple-
mentation of each intervention, personnel, supplies,
travel, and equipment). We will identify resource use
costs (hospitalizations, clinic, observation, and ER visits)
for both groups. Resource use costs will be obtained from
publically available data, e.g. Hospital Compare, Hospital
Stats, H-CUP. The DRG will be obtained with a conver-
sion rate and then adjusted by hospital specific informa-
tion, e.g. academic, location.
Discussion
This is the first fully-powered, randomized, controlled
trial to determine the effectiveness of a System-
CHANGE™ intervention in increasing medication adher-
ence in adult kidney transplant recipients. The sample
population is adult kidney transplantation recipients.
The results of this study can potentially impact the sci-
ence of adherence research radically for an extended
period of time. Adherence intervention research is lan-
guishing with modest results for over 35 years. Medica-
tion adherence intervention studies traditionally target
individuals’ characteristics, such as knowledge, attitudes,
and beliefs. They are marginally effective for those with
acute and chronic illnesses [14–16, 67] and ineffective
for adult transplant recipients [19, 20]. Clinicians are
frustrated by their inability to offer patients effective
medication adherence interventions. Patients are tired of
being blamed for medication nonadherence. We need ef-
fective interventions immediately to prevent loss of im-
planted kidneys, but also to make additional kidneys
available to those waiting for transplants by reducing the
number of transplant recipients who must rejoin the
transplant waiting list because medication non-
adherence caused their kidney transplant to fail. The im-
pact of the intervention on other health outcomes and
healthcare charges must be examined. We need a para-
digm shift from focusing on medication adherence pa-
tient knowledge, attitudes, beliefs, and behavioral skills
to the patient’s personal environment and daily routines
that influence MA [68].
If this SystemCHANGE™ intervention is found to be
effective in kidney transplant patients, other chronically
ill populations known to have medication nonadherence
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(those with hypertension, diabetes, TB, asthma, epilepsy)
may immediately benefit from this approach while trials
are conducted to confirm findings across populations.
The obdurate problem of medication nonadherence is
rampant. Scientists’ medication nonadherence interven-
tions will move from focusing primarily on interventions
to change knowledge, attitudes, and beliefs and instead
are focusing on changing the personal environment and
shaping daily routines. Clinicians will cease blaming the
patient for the inability to adhere to the prescription, but
will, within the SystemCHANGE™ framework, support
patient-designed, interventionist-guided, small experi-
ments using Deming’s Plan-Do-Check-Act cycle [69]
Our pilot study results indicate that the System-
CHANGE™ intervention “dose” may be effective immedi-
ately. If these results are supported in this larger study,
clinicians could quickly and easily deliver the interven-
tion in the hospital or clinic setting at a reasonable cost.
Electronic monitoring systems are constantly improving.
Wireless systems are streamlining electronic monitoring
of medications, which further enhances the ease of deliv-
ery. The findings of this study may also prompt re-
searchers to explore SystemCHANGE™ approaches to
changing other important public health problems arising
from human behavior (e.g. smoking).
In conclusion, each year, 35.6 kidney transplant recipients
per 100 are non-adherent with their medications, which is
the primary cause of post-transplant morbidity [8]. Thus,
the need for effective interventions is compelling: Decreas-
ing transplant complications from medication nonadher-
ence will reduce costs and make additional kidneys
available to those waiting for transplants by reducing the
number of kidney transplant recipients who must rejoin
the organ list. This project builds on our research team’s
previous adherence work, including a SystemCHANGE™
intervention pilot study that addresses Healthy People 2020
initiatives of reducing chronic kidney disease complications,
disability, death, and costs by optimizing transplant medica-
tion adherence and increasing the number of patients who
receive a transplant [70]. Evidence suggests that a signifi-
cant gap exists in the medication adherence intervention
literature – a lack of changing the personal environment
that either hinders or augments medication adherence. This
study addresses that gap in that it is the first to evaluate a
SystemCHANGE™ intervention to enhance medication ad-
herence in kidney transplant patients in a fully powered
study.
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